抗肿瘤坏死因子α与托珠单抗治疗难治性葡萄膜炎性黄斑水肿的比较:法国葡萄膜炎网络多中心研究
该多中心回顾性观察研究纳入204例对全身糖皮质激素或改善病情抗风湿药难治的成人葡萄膜炎性黄斑水肿患者,比较抗肿瘤坏死因子α药物与托珠单抗的疗效。6个月时托珠单抗组完全缓解率35.8%、总缓解率58.5%,抗肿瘤坏死因子α组分别为21.8%和46.2%;多因素分析显示托珠单抗与完全缓解独立相关(OR 2.10,95%CI 1.06-4.06,P=0.03)。两组复发率、低视力发生率和激素节约效应无显著差异。
要点
- 6个月总缓解率:抗肿瘤坏死因子α组46.2%(完全缓解21.8%) vs 托珠单抗组58.5%(完全缓解35.8%)。
- 多因素分析显示托珠单抗与完全缓解独立相关(OR 2.10,95%CI 1.06-4.06,P=0.03)。
- 两组复发率(HR 1.00,95%CI 0.31-3.18,P=0.99)、低视力(OR 1.02,95%CI 0.51-2.07,P=0.95)及激素节约效应(P=0.29)无显著差异。
核心结论
- 托珠单抗似乎较抗肿瘤坏死因子α药物提高葡萄膜炎性黄斑水肿的完全缓解率。
研究设计与样本
- 多中心、回顾性、观察性研究,纳入204例对全身糖皮质激素或改善病情抗风湿药难治的成人葡萄膜炎性黄斑水肿患者。
主要发现
- 6个月总缓解率:抗肿瘤坏死因子α组46.2%(完全缓解21.8%) vs 托珠单抗组58.5%(完全缓解35.8%)。
- 多因素分析中托珠单抗与完全缓解独立相关(OR 2.10,95%CI 1.06-4.06,P=0.03)。
- 两组复发率(HR 1.00,95%CI 0.31-3.18,P=0.99)、低视力发生率(OR 1.02,95%CI 0.51-2.07,P=0.95)及激素节约效应(P=0.29)无显著差异。
- 20.6%的患者报告不良事件,其中10.8%报告严重不良事件。
关键数值与推荐
- 抗肿瘤坏死因子α方案:英夫利西单抗5 mg/kg于第0、2、6周及之后每4-6周给药(n=69);阿达木单抗40 mg每2周给药(n=80)。
- 托珠单抗方案:8 mg/kg每4周静脉给药(n=39);162 mg每周皮下给药(n=16)。
- 主要结局为6个月时的完全缓解率、部分缓解率、复发率、低视力(至少1眼视力≥1 logMAR)、激素节约效应及不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the factors associated with response (control of ocular inflammation and corticosteroid-sparing effect) to biologics (anti-tumor necrosis factor [TNF]-α agents and tocilizumab) in patients with refractory uveitic macular edema (ME). DESIGN: Multicenter, retrospective, observational study. PARTICIPANTS: Adult patients with uveitic ME refractory to systemic corticosteroids, disease-modifying antirheumatic drugs, or both. METHODS: Patients received anti-TNF-α agents (infliximab 5 mg/kg at week 0, 2, 6, and every 4-6 weeks [n = 69] and adalimumab 40 mg/2 weeks [n = 80]) and tocilizumab (8 mg/kg every 4 weeks intravenously [n = 39] and 162 mg/week subcutaneously [n = 16]). MAIN OUTCOME MEASURES: Analysis of complete and partial response rates, relapse rate, low vision (visual acuity in at least 1 eye of ≥ 1 logarithm of the minimum angle of resolution), corticosteroid-sparing effect, and adverse events at 6 months. RESULTS: Two hundred four patients (median age, 40 years [interquartile range, 28-58 years]; 42.2% men) were included. Main causes of uveitis included Behçet's disease (17.2%), birdshot chorioretinopathy (11.3%), and sarcoidosis (7.4%). The overall response rate at 6 months was 46.2% (21.8% of complete response) with anti-TNF-α agents and 58.5% (35.8% of complete response) with tocilizumab. In multivariate analysis, treatment with tocilizumab (odds ratio, 2.10; 95% confidence interval [CI], 1.06-4.06; P = 0.03) was associated independently with complete response of uveitic ME compared with anti-TNF-α agents. Anti-TNF-α agents and tocilizumab did not differ significantly in terms of relapse rate (hazard ratio, 1.00; 95% CI, 0.31-3.18; P = 0.99) or occurrence of low vision (odds ratio, 1.02; 95% CI, 0.51-2.07; P = 0.95) or corticosteroid-sparing effect (P = 0.29). Adverse events were reported in 20.6% of patients, including serious adverse events reported in 10.8% of patients. CONCLUSIONS: Tocilizumab seems to improve complete response of uveitic ME compared with anti-TNF-α agents.
引用
- Leclercq M, Andrillon A, Maalouf G, et al. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network. Ophthalmology. 2021. PMID: 34793830. doi:10.1016/j.ophtha.2021.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。